IN10018 and dalpiciclib for progressive meningioma
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This trial tests a combination of two oral drugs, IN10018 and dalpiciclib, for people with progressive meningioma (a type of brain tumor) that has not responded to standard treatments. The goal is to see if this combination can help shrink or slow the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have a type of meningioma that is either Grade 2, Grade 3, or a Grade 1 that has come back after treatment
- Standard treatments (surgery, radiation, or other drugs) have not worked or are not available for you
- It has been at least 6 months since you finished radiation therapy
- Your blood cell counts, liver, kidney, and other organ functions are within a certain range (your doctor will check)
- You have not had a FAK inhibitor or a CDK4/6 inhibitor (like palbociclib) before
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies cabozantinib, a targeted pill medicine, for meningioma that has come back or is getting worse after standard treatment like surgery or radiation. It aims to shrink tumors and slow progression when other options may have limited benefit.
This trial tests abemaciclib, a targeted medicine, to see if it can help people with newly diagnosed grade 3 meningioma after standard radiation treatment. It may help by slowing tumor growth or improving outcomes after initial therapy.
This trial tests a drug called Zanzalintinib for people with meningioma that has come back or grown despite past treatments. It aims to see if the drug can stop or slow tumor growth.
This study tests a new drug called JZP3507 for people with meningioma (a type of brain tumor, grades 2 or 3) that has come back or grown despite previous treatment. The goal is to see if this medication can slow or shrink the tumor.
This trial tests a new targeted therapy pill (dalpiciclib) combined with hormone therapy for women with advanced breast cancer that is hormone-receptor positive and HER2-negative. It may help shrink tumors or slow their growth when chemotherapy is not an option.
This trial tests a new combination of two drugs (dalpiciclib and an HDAC inhibitor) for people with hormone receptor-positive, HER2-negative advanced breast cancer that has progressed after a CDK4/6 inhibitor. The goal is to see if this combination can help control the cancer.
Hear when a new Meningioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.